Stephanie Davis
Stock Analyst at Barclays
(0.59)
# 4,105
Out of 5,182 analysts
98
Total ratings
31.88%
Success rate
-106.22%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Overweight | $210 → $225 | $195.05 | +15.36% | 8 | Feb 11, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $25.23 | +78.36% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $6.37 | -21.51% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $24.57 | +205.25% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.67 | -8.74% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.32 | +158.62% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $3.62 | +424.86% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $311.99 | -7.05% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $205.61 | -35.31% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $45.51 | +27.44% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $5.19 | -42.20% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $0.75 | $9.80 | -92.35% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $259.57 | -4.07% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $9.42 | +207.86% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $6.00 | +466.67% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $18.38 | +84.98% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $158.49 | +47.01% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $1.34 | +1,173.41% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $81.18 | -6.38% | 5 | Jun 7, 2022 |
Quest Diagnostics
Feb 11, 2026
Maintains: Overweight
Price Target: $210 → $225
Current: $195.05
Upside: +15.36%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $25.23
Upside: +78.36%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $6.37
Upside: -21.51%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $24.57
Upside: +205.25%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.67
Upside: -8.74%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.32
Upside: +158.62%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $3.62
Upside: +424.86%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $311.99
Upside: -7.05%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $205.61
Upside: -35.31%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $45.51
Upside: +27.44%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $5.19
Upside: -42.20%
Oct 10, 2024
Maintains: Underweight
Price Target: $0.75
Current: $9.80
Upside: -92.35%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $259.57
Upside: -4.07%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $9.42
Upside: +207.86%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $6.00
Upside: +466.67%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $18.38
Upside: +84.98%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $158.49
Upside: +47.01%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $1.34
Upside: +1,173.41%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $81.18
Upside: -6.38%